Boston Scientific’s $1.75 Billion Acquisition of Baylis Medical Company

Shearman & Sterling advised Boston Scientific Corporation on the deal.

Boston Scientific Corporation (NYSE: BSX) executed its definitive agreement to acquire Baylis Medical Company for a purchase price of $1.75 billion, subject to customary purchase price adjustments. The transaction is expected to close in the first quarter of 2022, subject to the satisfaction of customary closing conditions for similar transactions.

The acquisition will expand the Boston Scientific electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG® and VersaCross® Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access.

Headquartered in Canada, Baylis Medical Company is a leader in the development and commercialization of innovative medical devices in the field of cardiology.

Boston Scientific develops, manufactures and distributes a wide array of products to meet the needs of a health care professionals and patients globally.

The Shearman & Sterling team included Clare O’Brien (Picture), Derrick Lott, Christopher Glenn, Gillian Emmett Moldowan, Jordan Altman, Jay M. Singer, Jason Pratt, Lorenz Haselberger, Melisa Brower, Teri Tillman, Andrew Calamari, Austin Grossfeld, and Eugene Kim.

Involved fees earner: Jordan Altman – Shearman & Sterling; Melisa Brower – Shearman & Sterling; Gillian Emmett Moldowan – Shearman & Sterling; Christopher Glenn – Shearman & Sterling; Lorenz Haselberger – Shearman & Sterling; Derrick Lott – Shearman & Sterling; Clare O’Brien – Shearman & Sterling; Jason Pratt – Shearman & Sterling; Jay Singer – Shearman & Sterling; Teri Tillman – Shearman & Sterling;

Law Firms: Shearman & Sterling;

Clients: Boston Scientific Corporation;